Can open-source R&D reinvigorate drug research?

  title={Can open-source R\&D reinvigorate drug research?},
  author={Bernard H. Munos},
  journal={Nature Reviews Drug Discovery},
  • B. Munos
  • Published 1 September 2006
  • Medicine
  • Nature Reviews Drug Discovery
The low number of novel therapeutics approved by the US FDA in recent years continues to cause great concern about productivity and declining innovation. Can open-source drug research and development, using principles pioneered by the highly successful open-source software movement, help revive the industry? 

Figures and Tables from this paper

Is Open Science the Future of Drug Development?
  • Daniel L. Shaw
  • Business, Medicine
  • The Yale journal of biology and medicine
  • 2017
This perspective argues that while open science poses some risks—which include the management of collaboration and the protection of proprietary data—these strategies are, in many cases, the more efficient and ethical way to conduct biomedical research. Expand
Open Source Drug Discovery: Finding a Niche (or Maybe Several)
Despite their novelty and importance, open source methods have been largely been limited to software. However, scholars have long suggested that it would be logical to organize at least one otherExpand
Is open innovation the way forward for big pharma?
The current, fully integrated business model of large pharmaceutical companies is increasingly considered to be unsustainable, and so new approaches that engage large and small companies, governmentsExpand
Pharmaceutical Research and Development: A Key Informant Assessment of Whether an “Open-Science” Model Could Improve Clinical Research in Terms of Quality and Efficiency
s or summaries (when available) of potential articles were reviewed and included if they: 1) contained directly collected or imputed data on pharmaceutical development costs; 2) were in English; andExpand
Lessons from 60 years of pharmaceutical innovation
  • B. Munos
  • Medicine
  • Nature Reviews Drug Discovery
  • 2009
Analysis of the record of pharmaceutical innovation by analysing data on the companies that introduced the ∼1,200 new drugs that have been approved by the FDA since 1950 shows that the new-drug output from pharmaceutical companies in this period has essentially been constant, and remains so despite the attempts to increase it. Expand
The impact of open IP platforms on IP-strategy norms in Life Sciences
In the biomedical fi eld multiple stakeholders may collaboratively develop, package and build transactions around technology. This is often referred to as open innovation, open biotechnology or openExpand
Open science is a research accelerator.
An open-source approach to the problem of producing an off-patent drug in enantiopure form serves as an example of how academic and industrial researchers can join forces to make new scientificExpand
Open Access Could Transform Drug Discovery: A Case Study of JQ1
JQ1 serves as a test case to evidence that open access drug discovery can be an economic model that potentially improves efficiency and cost of drug discovery and its subsequent commercialization, and counter the notion that openAccess drug discovery would leak commercial intellectual property. Expand
Bio-Business in Brief: A Case for New Drugs at Generic Prices from India
The authors propose a hypothetical organization that brings drugs to market by working with a network of academic and corporate partners, and primarily working in India, and in this model new drugs would be available at generic prices from day one. Expand
Open innovation: An opportunity for Pharmerging countries to close the technology gap?
The pharmaceutical industry is entering a critical phase in its history, with decliningprofits and patent cliffs fallouts awaiting their former blockbuster drugs. Several hypotheseshave beenExpand


The case for open-source software in drug discovery.
  • W. Delano
  • Biology, Medicine
  • Drug discovery today
  • 2005
Why and how consumers in drug discovery will benefit from new open-source products that address their needs with increased flexibility and in ways complementary to proprietary options are predicted. Expand
Science & society: Virtual drug discovery and development for neglected diseases through public–private partnerships
The focus on virtual drug discovery and development as operationalized through public–private partnerships brings many advantages, as well as scientific and managerial challenges. Expand
The Major Role of Clinicians in the Discovery of Off‐Label Drug Therapies
The role of clinicians in the discovery of off‐label use of prescription drugs approved by the United States Food and Drug Administration is investigated. Expand
Finding Cures for Tropical Diseases: Is Open Source an Answer?
The Tropical Disease Initiative will be a Web-based, community- wide effort where scientists from the public and private sectors join together to discover new treatments
The Open Source Biotechnology Movement: Is it Patent Misuse?
Fledgling efforts exist to establish open-source projects in biotechnology. Following copyleft, participants agree that advances in the technology must remain as openly available as the originalExpand
Open Source Biotechnology
Dramatic recent expansion of intellectual property protection in the field of biotechnology has led to concerns that ongoing innovation will be blocked unless action is taken to preserve access toExpand
Open and Collaborative Research: A New Model for Biomedicine
The advent of open source software has prompted some theoretical speculation about the applicability of open source production principles to biomedical research. This paper moves beyond theoreticalExpand
Technology Licensing to Non-Traditional Partners
The commercialization of technologies arising from university research depends on the ability of technology managers to find and contract with appropriate development partners. Substantial investmentExpand
Optimizing the use of open-source software applications in drug discovery.
This review investigates the application of free and/or open-source software in the drug discovery process, finding programs programmed in JAVA, Perl and Python might be useful for cheminformatics approaches to drug discovery. Expand
Creating a Tradition of Biomedical Research
Library of Congress Cataloging-in-Publication Data Creating a tradition of biomedical research: contributions to the history of the Rockefeller University / edited by Darwin H. Stapleton. p. cm.Expand